Drug Profile
Research programme: cancer-associated pain therapeutics - Benitec/Stanford University
Alternative Names: BLTPKC3&4; BLTPKC4Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Benitec Biopharma
- Developer Benitec Biopharma; Stanford University
- Class Small interfering RNA
- Mechanism of Action Gene silencing; Protein kinase C gamma inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer-pain in Australia (Intrathecal, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer-pain in USA (Intrathecal, Injection)
- 22 May 2013 Preclinical trials in Cancer pain in Australia (Intrathecal)